Educational programme EBAC

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Some of the sessions of the Educational Programmes are still pending for EBAC accreditation.

EBAC ACCREDITED EDUCATIONAL PROGRAMME

Sunday 06 May 14:30 - 15:30

Optimizing dyslipidaemia management: the value of combination therapy

The “Optimizing dyslipidemia management: the value of combination therapy”, is accredited by the European Board for Accreditation In Cardiology (EBAC) for 1 CME credit hour (s). EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Chair:
  • Olov Wiklund, Sweden
  • Alberto Mello e Silva, Portugal
  • The CV benefit of combination therapy

    Christopher Cannon, Boston, USA

  • Incremental value of established therapies for dyslipidaemic patients

    Luis Masana, Reus, Spain

EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Sanofi in support of the Programme.


Monday 07 May 13:30 - 15:00

Therapeutic approaches to the very high risk patient: what is new?

The “Therapeutic approaches to the very high risk patient: what is new?”, is accredited by the European Board for Accreditation In Cardiology (EBAC) for 1 CME credit hour (s). EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Chair:
  • Lale Tokgozoglu, Turkey
  • Jennifer Robinson, USA
  • Lipids, inflammation and cardiovascular risk

    Erik S. Stroes, Amsterdam, The Netherlands

  • PCSK9 inhibition in high risk patients

    Gabriel P. Steg, Paris, France

  • The ideal patient for PCSK9

    J. Wouter Jukema, Leiden, The Netherlands

EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Sanofi and Regeneron in support of the Programme.


Monday 07 May 14:30 - 15:30

Omega 3 fatty acids: their role in cv prevention

The “Omega 3 fatty acids: their role in cv prevention”, is accredited by the European Board for Accreditation In Cardiology (EBAC) for 1 CME credit hour (s). EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Chair:
  • Giuseppe Danilo Norata, Italy
  • Alexandros Tselepis, Greece
  • Omega 3 fatty acids & hepatic lipid metabolism

    Eleonora Scorletti, Southampton, United Kingdom

  • Clinical trials in evaluating OMEGA 3 fatty acids in CV disease

    Aldo P. Maggioni, Florence, Italy

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge partial financial support, in the form of an educational grant, received from Amarin in support of the Programme.


Sunday 06 May 13:30 - 15:00

From nutrition to personalized nutrition in dyslipidaemias

The “From nutrition to personalized nutrition in dyslipidaemias”, is accredited by the European Board for Accreditation In Cardiology (EBAC) for 1 CME credit hour (s). EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Chair:
  • Michal Vrablík, Czech RepubliC
  • Philippe Moulin, France
  • Food4me: The experience

    Mike Gibney, Dublin, Ireland

  • Reducing cholesterol by dietary means

    Eric Bruckert, Paris, France

  • Dietary fat vs Carbohydrates

    Gabriele Riccardi, Naples, Italy

EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from BASF/Raisio/Unilever in support of the Programme.


EBAC ACCREDITATION PENDING

Saturday 05 May 16:20 - 17:50

Patient journey after acute coronary syndromes: can we improve outcomes?

Chair:
  • Jan Borén, Sweden
  • Peter Toth, USA
  • Optimising therapy through cardiac rehabilitation

    Anselm Gitt, Ludwigshafen, Germany

  • Hospital management after acute coronary syndromes: Is the risk over?

    José Luis Zamorano, Madrid, Spain

  • Science versus reality in long term management: Time for a paradigm shift?

    Lale Tokgozoglu, Ankara, Turkey

EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from MSD in support of the Programme.


Sunday 06 May 13:30 - 14:30

Exploring new metabolic pathways to control dyslipidaemias

Chair:
  • Kausik Ray, United Kingdom
  • Christoph Binder, Austria
  • Validating pharmacological targets by genetics: the case of ATP Citrate Lyase

    Brian A. Ference, Cambridge, United Kingdom

  • Bempedoic acid: the clinical experience

    Maciej Banach, Lodz, Poland

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Esperion in support of the Programme.


Monday 07 May 13:30 - 14:30

New targets for controlling dyslipidaemias and atherosclerosis

Chair:
  • Ruth Frikke-Schmidt, Denmark
  • Paolo Parini, Sweden
  • Silencing genes, new targets

    Sotirios (Sam) Tsimikas, San Diego, USA

  • Apolipoprotein CIII silencing: the benefit in FCS

    Marcello Arca, Rom, Italy

EAS have independently organised all matters related to this 60-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Akcea in support of the Programme.


Monday 07 May 13:30 - 15:00

Lowering atherogenic lipoproteins: the cv benefit

Chair:
  • Marja-Riitta Taskinen, Finland
  • Arnold von Eckardstein, Switzerland
  • Apo B containing lipoproteins a better target for CV risk reduction?

    Brian A. Ference, Cambridge, United Kingdom

  • How to control atherogenic dyslipidaemia

    Henry Ginsberg, New York, USA

  • Combination therapy: When and how

    Michel Farnier, Dijon, France

EAS have independently organised all matters related to this 90-minute Programme, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Mylan in support of the Programme.